A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Registration Number
- NCT01043276
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study if to investiagte the time course of PF-00258210 plasma concentration in the presence or absence of PF-00610335 administered via oral inhalation using dry powder inhalers
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive
Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
Exclusion Criteria
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
- A positive urine drug screen
- Pregnant or nursing females
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Treatment E Treatment E - Treatment A Treatment A - Treatment B Treatment B - Treatment C Treatment C - Treatment D Treatment D -
- Primary Outcome Measures
Name Time Method plasma pharmacokinetics AUClast and Cmax Day 1
- Secondary Outcome Measures
Name Time Method plasma pharmacokinetics, AUCinf and Tmax Day 1
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇸🇬Singapore, Singapore